Intratympanic glucocorticosteroid therapy for idiopathic sudden hearing loss

Meta-analysis of randomized controlled trials

Dan Lai, MD\textsuperscript{a,b}, Fei Zhao, MD, PhD\textsuperscript{c,d}, Nasim Jalal, BS\textsuperscript{c}, Yun Zheng, MD\textsuperscript{a,*}

Abstract

Background and objective: Glucocorticoids are the standard treatment for idiopathic sudden sensorineural hearing loss (ISSNHL), but whether intratympanic or systemic therapy is superior remains controversial. Previous meta-analyses of this question have omitted key clinical trials or included observational studies.

Methods: English-language randomized controlled trials in OvidSP, PubMed, Embase, CINAHL, and the Cochrane Library comparing intratympanic versus systemic glucocorticoid therapy for ISSNHL were meta-analyzed using RevMan 5.3. The primary outcome of interest was improvement in pure tone average (PTA) threshold.

Results: Six trials involving 248 patients receiving intratympanic steroids and 236 receiving systemic steroids were meta-analyzed. PTA thresholds were similar between the 2 groups at 3 months after therapy initiation (mean difference, 0.24; 95% confidence interval [CI] –2.43 to 2.91, \( P = .86 \); \( I^2 = 54\% \), \( P = .07 \), random-effects model). PTA thresholds were also similar at 6 months (mean difference, 4.69, 95% CI –5.84 to 15.22, \( P = .38 \)), although the results showed extremely high heterogeneity (\( I^2 = 98\% \)). Sensitivity analysis indicated that a single trial containing 250 patients provided the strongest evidence for equivalence between the 2 types of therapy. Rates of recovery within 3 months (defined as PTA improvement >10 dB) were similar between the 2 types of therapy (odds ratio 0.92, 95% CI 0.59–1.43, \( P = .70 \)), with no significant heterogeneity in the pooled data (\( I^2 = 1\% \), \( P = .40 \)).

Conclusion: Intratympanic and systemic steroids’ therapies appear to show similar short-term efficacy for restoring hearing in patients with ISSNHL. Intratympanic therapy may reduce systemic side effects associated with steroid use.

Abbreviations: CI = confidence interval, ISSNHL = idiopathic sudden sensorineural hearing loss, OR = odds ratio, PTA = pure tone average, RCT = randomized controlled trial, WRS = word recognition score.

Keywords: idiopathic sudden sensorineural hearing loss, initial treatment, intratympanic steroid treatment, meta-analysis, systemic steroids

1. Introduction

Idiopathic sudden sensorineural hearing loss (ISSNHL), defined as hearing loss of \( \geq 30 \text{ dB} \) in 3 consecutive frequencies of pure tone average (PTA) within 72 h,[1] is estimated to affect 5 to 20 people per 100,000 per year worldwide.[2] The causes of the condition are unknown but are more likely to be a spectrum of pathologies that affect the cochlea, rather than a single pathological change.[3] Primary treatment and interventions for this condition are the subject of ongoing debate, which is made more complex by the fact that 32% to 65% of patients spontaneously recover within 15 days from onset.[4–7] Among the numerous treatments tested,[8] oral/systemic steroid treatment is the most frequent primary treatment and is widely considered the most effective.[9]

However, systemic steroids are associated with significant side effects, including mood changes, loss of appetite, disrupted sleep patterns, increased thirst, weight gain, hypertension, and hyperglycemia. Therefore, this therapy should be considered carefully if patients have other chronic diseases, such as diabetes mellitus or glaucoma.[10] An alternative to systemic therapy is intratympanic therapy, first proposed by Silverstein et al in 1996,[11] Local steroid administration directly into the ear reduces the risk of systemic side effects and allows the steroid to penetrate directly into the cochlea and achieve a high concentration there even when low doses are used.[12,13] Steroids administered at the tympanic membrane are usually dexamethasone and solumedrol, which affect immune suppression and ion homeostasis.[14] The principle behind this therapy is that the steroid reduces inflammation associated with labyrinthitis, enhances cochlear blood flow, and improves striavalvar function.[15] In fact, intratympanic therapy can be an effective second-line therapy for patients who do not recover hearing after oral steroid treatment.[17,10,18–20] Despite its advantages, intratympanic steroid therapy is more...
expensive, requires multiple office visits, and is associated with pain, transient dizziness, infection, and persistent tympanic membrane perforation.\(^{11}\)

The evidence base is unclear on how intratympanic or systemic steroid therapy compare as primary treatments for ISSNHL. Some studies have found the 2 to be equivalent,\(^{21,22}\) while others have found intratympanic therapy to be superior.\(^{23-25}\) While 1 meta-analysis\(^{26}\) concluded that intratympanic therapy is superior to systemic therapy, other meta-analyses have found the 2 types of therapy to be equivalent.\(^{18,27,28}\) At the same time, some work has shown intratympanic administration to be inferior to combination therapy involving intratympanic dexamethasone and high-dose prednisone taper.\(^{29}\) These discrepancies in the literature prevent definitive conclusions about the optimal primary treatment for ISSNHL.

Since these discrepancies are likely due to inclusion of studies that were not exclusively randomized clinical trials (RCTs) and of studies in which patients were treated with combination therapies, we wished to review and meta-analyze relevant evidence only from RCTs comparing intratympanic and systemic steroid therapy as single therapies, not in combination with other treatments. RCTs can provide the most rigorous assessments to guide clinical practice.\(^{30}\)

2. Methods

2.1. Search strategy and data sources

The literature search was guided by the following problem formulation in the PICOS format: population of interest (P), participants suffering from sudden onset of ISSNHL; intervention (I), participants receiving intratympanic steroids as initial treatment; comparison (C), participants receiving oral/systemic steroids as initial treatment; outcome (O), hearing recovery as well as adverse events; study design (S), RCT.\(^{31}\)

All potentially relevant RCTs published up to December 2016 were systematically identified by searching Medline on OvidSP, PubMed, Embase, CINAHL, and the Cochrane Library. An additional search of the gray literature was performed accessing Google Scholar. Furthermore, hand searches of the references from the included studies were performed. The search strategy was similar for all databases and is exemplified here for the case of PubMed: (1) sudden hearing loss, (2) idiopathic sudden sensorineural hearing loss, (3) sudden sensorineural hearing loss, (4) sudden deafness, (5) (1–4) OR, (6) systemic steroids, (7) oral steroids, (8) intratympanic, (9) (6–8) OR, and (10) (5 AND 9).

2.2. Inclusion and exclusion criteria

This study was approved by the Ethics in Research Committee at West China Hospital of Sichuan University. Search results were limited to human studies published in English that reported the change in PTA thresholds and the proportion of patients showing improved hearing after treatment.\(^{29,32}\) These were the primary outcomes of the analysis, while secondary outcomes were word recognition score (WRS) and adverse events.

We excluded case studies, case series, qualitative studies, noncontrolled studies, editorials, and books. Duplicate publications and studies involving steroid therapies delivered in combination with other treatments were also excluded.

2.3. Study selection, data extraction, and quality assessment

Titles and abstracts of all retrieved citations were screened independently by 2 authors (DL and FZ) to identify potentially relevant studies. Discrepancies were resolved by discussion. The following data were extracted independently by the same 2 authors using a standard form: general information, trial design, participant baseline characteristics, interventions, outcomes, and conclusions.

The same 2 authors then independently assessed the methodological quality of the included RCTs. Discrepancies were resolved by discussion. Risk of bias was assessed using the recommendations in the Cochrane Handbook for Systematic Interventions (version 5.1.0, http://www.handbook.cochrane.org),\(^{33}\) which focuses on bias related to randomization sequence generation, allocation concealment, blinding of participants or healthcare providers, incompleteness, reporting, and other issues.

2.4. Statistics and data analysis

Rev Man 5.3 software was used for all statistical analysis, with a significance threshold of \(P < .05\). Dichotomous outcomes were analyzed by calculating odds ratios (ORs) and the corresponding 95% confidence intervals (CIs). Continuous outcomes were analyzed by calculating the mean difference and 95% CI. The type of meta-analysis model depended on whether significant heterogeneity was present in the pooled data. If \(I^2\) value was \(< 50\), the fixed model was used; otherwise, the random model was used. Heterogeneity was assessed using the chi-squared and \(I^2\) tests, with \(I^2 > 50\%\) considered as significant heterogeneity.\(^{34}\) In cases of heterogeneity, potential causes were analyzed. Sensitivity analysis was also performed to assess the stability of results.

3. Results

3.1. Literature search

Literature searching initially turned up 105 potentially relevant studies (Fig. 1), of which 23 were read in full. Intratympanic steroid therapy was the primary treatment in 15 studies, while oral/systemic steroid therapy was the treatment in the remaining studies. In the end, 6 RCTs were included: 1 multicenter, double-blind study and 5 single-center prospective studies (Table 1).

The 6 studies\(^{29,32,35-38}\) involved 484 participants with ages ranging from 20 to 83 years and a male:female ratio of 1.4:1. Intratympanic therapies involved either dexamethasone or methylprednisolone. Doses and duration of therapies varied.
Lai et al. Medicine (2017) 96:50 www.md-journal.com

Table 1

Characteristics of the included studies.

| Study | Time from start to therapy initiation, d | Steroid and Schedule | Administration | Time from start to outcome assessment, d | Outcome assessment, d |
|-------|----------------------------------------|----------------------|---------------|------------------------------------------|-----------------------|
| Battaglia 2008 | 21 | Patients (mean age, 60), 0.7 mL, 12.0 mg/mL | Dexamethasone | Intravenous injection | 30 mg 4-0 mg 4 d, 30 mg 4 d, 30 mg 4 d, 20 mg 2 d, 10 mg 1 d |
| Hong 2009 | 20 | Patients (mean age, 56), 24 Patients, 25 controls; mean age of all subjects, 43.4 ± 11.9; M:F ratio, 42:31 | Dexamethasone (4 mg/mL) | Intravenous injection | 4 mg 1 d, 10 mg 1 d, 20 mg 1 d, 30 mg 1 d |
| Kosyakov 2011 | 30 | Patients (mean age, 60), 6.8 (mean) | Dexamethasone | Intravenous injection | 4 mg 1 d, 10 mg 1 d, 20 mg 1 d, 30 mg 1 d |
| Dispenza 2011 | 10.1 ± 1.6 (mean) | Patients vs. 21 controls; mean age of all subjects, 50.9 ± 1.8; M:F ratio, 150:100 | Methylprednisolone: 40 mg/mL | Intravenous injection | 4 mg 1 d, 10 mg 1 d, 20 mg 1 d, 30 mg 1 d |
| Lim 2013 | 129 Patients, 121 controls; mean age of all subjects, 43.4 ± 11.9; M:F ratio, 42:31 | Patients vs. 21 controls; mean age of all subjects, 50.9 ± 1.8; M:F ratio, 150:100 | Dexamethasone: 4 doses over 2 wk instilled through the injection site | Intravenous injection | 4 mg 1 d, 10 mg 1 d, 20 mg 1 d, 30 mg 1 d |

3.2. Comparative efficacy of intratympanic or systemic steroid therapy

Five studies reported no significant differences in average PTA improvement or recovery rate between the intratympanic and systemic treatment groups at 1 to 3 months after therapy initiation (P > 0.05). Three studies assessed hearing outcomes at 6 months; 2 of them found no significant difference, while 1 study found intratympanic therapy to be associated with greater hearing recovery (P < 0.05). Studies varied substantially in how they calculated PTA thresholds, how they defined hearing recovery, and when they assessed recovery for the last time. For example, 1 study calculated PTA using 3 low- and mid-frequencies, while the remaining 5 studies used 4 frequencies. The final assessment time point varied between 21 days and 6 months among the 6 studies. The outcomes assessment was shown in Table 2.

Meta-analysis was performed on outcome assessments at 1 to 3 months in 5 trials. No significant difference in PTA improvement was observed between intratympanic and systemic therapy (mean difference, 0.24; 95% CI −2.43 to 2.91; P = 0.86; I² = 54%; P = 0.07; random-effects model; Fig. 2A). Subgroup analysis was not performed because of the small number of trials and the heterogeneity in dose and duration of intratympanic therapy.

Sensitivity analysis indicated that the sole trial of Rauch et al, which accounted for more than half the patients in the meta-analysis, was the most powerful evidence for equivalence between intratympanic and systemic therapy (Fig. 2B). Among the 3 studies reporting outcome assessment at 6 months, meta-analysis of pooled data showed similar PTA thresholds (mean difference, 4.69; 95% CI −5.84 to 15.22; P = 0.38) with significant heterogeneity (I² = 98%; Fig. 2C).

As another primary outcome, the rate of hearing recovery was compared between intratympanic and systemic steroid therapy. Three studies defined hearing recovery as an improved in PTA threshold >10 dB; the other 3 studies defined it as an improved >15 dB. Data pooled from 5 studies showed similar hearing recovery rates between the 2 types of treatment at 1 to 3 months (OR 0.92, 95% CI 0.59–1.43, P = 0.70) without significant heterogeneity among studies (I² = 1%, P = 0.40; Fig. 3A). Similar results were observed at 6 months (OR 1.56, 95% CI 0.52–4.68, P = 0.42), although heterogeneity was significant (I² = 61%; P = 0.08; Fig. 3B). Sensitivity analysis identified the study by Kosyakov et al as the cause of the heterogeneity.

Two studies compared therapeutic efficacy in terms of WRS at 1 to 2 months. Meta-analysis of data pooled from these studies revealed no significant difference between the 2 types of treatment (mean difference, 2.29; 95% CI −9.62 to 14.2, P = 0.42) with no significant heterogeneity (I² = 32%, P = 0.22; Fig. 3C).

3.3. Risk of bias

Despite being prospective RCTs, some studies showed high or unclear risk of selection and performance bias (Table 3). For example, the study by Rauch et al was a multicenter, prospective, randomized, noninferiority controlled trial with clearly detailed randomization and concealment procedures.
However, participants and physicians were not blinded to treatment, increasing risk of performance bias. The other 5 studies\[29,32,35–37\] had a similar blinding issue, and they also failed to describe in detail the randomization and allocation methods. Potential bias in meta-analysis was evaluated by funnel plots, as shown in Fig. 4, which indicated no obvious publication bias in our results.

3.4. Comparison of adverse effects

Adverse effects were reported in 1 study,[38] 4 studies reported that no side effects were observed,[29,32,36,37] and 1 study did not mention whether side effects occurred or not[35] (Table 4). In the study reporting adverse events, none of the events was serious. The major events in the intratympanic group were ear pain, transient vertigo, ear infection, and persistent tympanic membrane perforation. No systemic adverse events were observed in this group. The major events in the oral group were a decrease in blood glucose, changes in sleep or appetite, dry mouth/thirst and weight change; all these events occurred at significantly higher frequencies than in the intratympanic group. Similar proportions of patients in each treatment group suffered ear infection.

### Table 2

| Study            | Frequencies in PTA assessment, Hz | Criterion for hearing recovery | Final assessment time point | Initial PTA (dB HL) | Percent improvement | Conclusion                  |
|------------------|----------------------------------|-------------------------------|-----------------------------|---------------------|---------------------|-----------------------------|
| Battaglia 2008   | 500, 1000, 2000                  | PTA > 15 dB                   | 4 wk                        | 82 ± 28             | 70.6                | Trend for intratympanic to be superior to oral |
| Hong 2009        | 500, 1000, 2000                  | PTA > 15 dB                   | 3 mo                        | 77.5 ± 27.6         | Not available        | No significant difference between intratympanic and oral/systemic |
| Kosyakov 2011    | 500, 1000, 2000, and 3000        | PTA > 15 dB                   | 6 mo                        | 41.0 ± 12.87        | 88                  | Intratympanic superior at 6 mo |
| Dispenza 2011    | 500, 1000, 2000, and 4000        | PTA > 10 dB; WRS > 10%        | 6 mo                        | 86.4 ± 5.6          | 76.7                | No significant difference |
| Lim 2013         | 500, 1000, 2000, and 3000        | PTA > 10 dB                   | 21 d                        | 57.2 ± 28.5         | 55                  | No significant difference |

PTA = pure tone audiometry, WRS = word recognition score.

![Figure 2](image-url)
4. Discussion

Previous meta-analyses comparing intratympanic and oral/systemic steroid therapy as first-line treatment for ISSNHL have not resolved the controversy over which therapy is superior, probably in part because they included non-RCTs and heterogeneous treatment regimes in which intratympanic therapy was sometimes combined with other regimes. For example, 3 meta-analyses assessed only intratympanic steroid therapy used on its own, [18,27,28] while 3 others included intratympanic therapy combined with systemic therapy. [39–41]

Here, we meta-analyzed only RCTs that compared intratympanic therapy on its own with oral/systemic therapy on its own. We found that the 2 therapies gave similar hearing recovery at 1 to 3 months and potentially also at 6 months after initiation of treatment. Recovery was measured in terms of PTA thresholds and the proportion of patients meeting a defined recovery threshold.

| Table 3 Risk of bias assessment. |
|----------------------------------|
| Type of bias                     | Bias assessment (reference no.) | Support for risk assessment |
|----------------------------------|---------------------------------|-----------------------------|
| Random sequence generation (selection bias) | 1L [20]                      | The randomization method was clearly described |
|                                   | 1L [56]                      | The division into groups was based on mechanical randomization |
|                                   | 1L [36]                      | The method of randomization was a consecutive allocation by visit sequence |
| Allocation concealment (selection bias) | 3L [29,32,37]               | Method of randomization and allocation was not mentioned in detail |
| Blinding of participants and personnel (performance bias) | 1L [29]                      | Only personnel at the data coordinating center had access to the codes |
|                                   | 1L [36]                      | Allocation concealment was not mentioned |
| Blinding of outcome assessment (detection bias) | 3L [29,32,38]               | Treatment was administered in double-blind fashion |
|                                   | 3L [29,35,37]               | The method of blinding was not described in detail |
| Incomplete outcome data (attrition bias) | 6L [29,32,35–38]          | The participants and treating physicians were not blinded to treatment |
| Selective reporting (reporting bias) | 6L [29,32,35–38]          | Outcome assessors were blinded to the treatment |
| Other bias                        | 6L [29,32,35–38]          | The method of blinding was not described in detail |

H = high risk of bias, L = low risk of bias, U = uncertain risk of bias.
Dexamethasone appears to be the steroid most frequently used to treat ISSNHL. This synthetic corticosteroid is widely used as an anti-inflammatory agent delivered orally, parenterally, and topically. Studies suggest that dexamethasone is effective against ISSNHL because it decreases inflammation from labyrinthitis,\(^42\) improves cochlear blood flow,\(^41\) protects against cochlear ischemia,\(^44\) and improves striavascularis function. It may exert these effects by modulating Na\(^+\)/K\(^+\) ion exchange, helping to maintain endocochlear potential and thereby promoting hearing recovery.\(^45\) In addition to dexamethasone, methylprednisolone is recommended to treat ISSNHL.\(^38,46,47\) Pharmacokinetics studies show that it accumulates primarily in the inner ear.\(^12\)

The 6 studies in this meta-analysis showed substantial variation in the dose and duration of intratympanic steroid delivery. For example, total doses of intratympanic dexamethasone varied from 6 to 240 mg delivered over 8 days to 6 months. This highlights the need for greater standardization of intratympanic therapy.

Studies also differed substantially in how researchers analyzed improvement in PTA thresholds, with each study using a different frequency range. Some studies defined hearing recovery as a PTA increase >10\(^\text{dB}\)\(^{36-38}\) or >15 dB\(^{29,32,33}\). These observations highlight the need for greater standardization of hearing assessments during treatment of patients with ISSNHL. We suggest that future studies should aim to standardize the frequency range for PTA and should define normal variability in PTA thresholds as 5 to 10 dB,\(^48\) which argues for using >10 dB as the definition of hearing recovery.\(^1\) Hearing assessments during treatment for ISSNHL should also include calculation of the WRS,\(^1\) which was performed in only 2 trials.\(^29,38\)

Another aspect of intratympanic therapy yet to be standardized is the delivery system. In most studies, the steroid was delivered by transtympanic injection,\(^29,32,37,38\) which can be less invasive, safer, and more cost-effective than other methods. On the other hand, it can lead to early, uncontrollable loss of the steroid solution through the Eustachian tube.\(^49\) Another possibility is instillation of the steroid solution through a ventilation tube in the tympanic membrane,\(^33\) in which case the patient can administer the drug himself or herself. However, how much of the applied solution enters the inner ear is uncertain. Future studies should rigorously compare the various intratympanic delivery systems.

Finally, the present review makes clear a striking lack of safety assessment in studies of primary treatments for ISSNHL. Few studies in our review reported such data, despite being RCTs. While the available evidence hints that intratympanic therapy may be preferable to systemic therapy, more data of higher quality are needed in order to draw definitive conclusions. Future research should comprehensively examine the adverse events and side effects of intratympanic therapy.

### 5. Conclusion and future research

This review and meta-analysis of English-language RCTs found no evidence of significant difference in short-term hearing recovery obtained with intratympanic or oral/systemic steroid therapy for patients with ISSNHL. This supports the use of intratympanic therapy over systemic therapy when avoiding potential steroid side effects is more important, such as for patients with other chronic diseases. Review of the RCTs here indicates large gaps in our understanding of adverse events and long-term efficacy of intratympanic steroid therapy; it also highlights the need for standardized procedures for PTA-based assessment of hearing recovery.

### References

1. Stachler RJ, Chandrasekhar SS, Archer SM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 2012;146 (suppl): S1–S35.
2. Alexander TH, Harris JP, Nguyen QT, et al. Dose effect of intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss: 24 mg/mL is superior to 10 mg/mL. Otol Neurotol 2015;36:1321–7.

---

**Table 4:** Adverse events associated with intratympanic or oral/systemic steroid therapy.

| Adverse event                  | Intratympanic therapy, n/N (%) | Oral/systemic therapy, n/N (%) | P     |
|-------------------------------|--------------------------------|--------------------------------|-------|
| Mild pain                     | 35/129 (27.1)                  |                                |       |
| Tympanic membrane perforation | 5/129 (3.8)                    |                                |       |
| Short duration vertigo        | 35/129 (27.1)                  | 13/121 (10.7)                  | <.05  |
| Ear infection                 | 7/129 (5.4)                    | 2/121 (1.7)                    | >.05  |
| Blood glucose problem         | 21/129 (16.3)                  | 36/121 (29.8)                  | <.05  |
| Sleep change                  | 9/129 (7.0)                    | 44/121 (36.4)                  | <.05  |
| Weight change                 | 7/129 (5.4)                    | 22/121 (18.2)                  | <.05  |
| Dry mouth/thirst              | 5/129 (3.9)                    | 30/121 (24.8)                  | <.05  |

Data were taken from Rauch et al.\(^38\)
[3] Chau JK, Lin JR, Atashbadd S, et al. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope 2010;120:1011–21.

[4] Conlin AE, Barnes LS. Treatment of sudden sensorineural hearing loss: III. A meta-analysis. Arch Otolaryngol Head Neck Surg 2007;133:582–6.

[5] Mattorx DE, Simmons FB. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 1977;86:46:8–10.

[6] Fetterman BL, Saunders JE, Luxford WM. Prognosis and treatment of sudden sensorineural hearing loss. Am J Otol 1996;17:529–36.

[7] Ho HG, Lin HC, Shu MT, et al. Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope 2004;114:1184–9.

[8] Wei BP, Mubiru S, O'Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev 2006;CD003998.

[9] Wilson WR, Veleri RW, Laird N, et al. Viral and epidemiologic studies of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg 1983;91:633–8.

[10] Spear SA, Schwartz SR. Intratympanic steroids for sudden sensorineural hearing loss: a systematic review. Otolaryngol Head Neck Surg 2011;145:534–43.

[11] Silverstein H, Choo D, Rosenberg SI, et al. Intratympanic steroid treatment of inner ear disease and tinnitus: preliminary report. Eur Otorhinolaryngol Head Neck Surg 1996;75:646–71.

[12] Barnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999;109:1–7.

[13] Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otolaryngol Head Neck Surg 2001;22:18–23.

[14] Hamid M, Trune D. Issues, indications, and controversies regarding intratympanic steroid perfusion. Curr Opin Otolaryngol Head Neck Surg 2008;16:34–40.

[15] Seggas I, Koltsidopoulos P, Babis A, et al. Intratympanic steroid therapy for sudden sensorineural hearing loss: a review of the literature. Otol Neurotol 2011;32:29–35.

[16] Khammouk W, Jantaratapanna K. Therapy of idiopathic sudden sensorineural hearing loss with intratympanic steroid injection. J Med Assoc Thai 2011;94:1495–9.

[17] Plaza G, Herranz C. Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy. Otolaryngol Head Neck Surg 2007;137:74–8.

[18] Garavello W, Galluzzi F, Gaimi RM, et al. Intratympanic steroid treatment for sudden deafness: a meta-analysis of randomized controlled trials. Otol Neurotol 2012;33:724–9.

[19] Ng JH, Ho RC, Cheong CS, et al. Intratympanic steroids as a salvage treatment for sudden sensorineural hearing loss? A meta-analysis. Eur Arch Otorhinolaryngol 2015;272:2777–82.

[20] Haynes DS, O'Malley M, Cohen S, et al. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007;117:3–15.

[21] Dallan I, Fortunato S, Casani AP, et al. Long-term follow up of sudden sensorineural hearing loss patients treated with intratympanic steroids: audiological and quality of life evaluation. J Laryngol Otol 2014;128:669–73.

[22] Kakehata S, Sasaki A, Oji K, et al. Comparison of intratympanic and intravenous dexamethasone treatment on sudden sensorineural hearing loss with diabetes. Otol Neurotol 2006;27:604–8.

[23] Han CS, Park JR, Boo SH, et al. Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes. Otolaryngol Head Neck Surg 2009;141:572–8.

[24] Labatut T, Daza MJ, Alonso A. Intratympanic steroids as primary initial treatment of idiopathic sudden sensorineural hearing loss. The Hospital Universitario Ramon y Cajal experience and review of the literature. Eur Arch Otorhinolaryngol 2013;270:2823–32.

[25] Kara E, Cetik F, Tarkan O, et al. Modified intratympanic treatment for idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 2010;267:701–7.

[26] Qiang QWX, Yang T, Yang C, et al. A comparison between systemic and intratympanic steroid therapies as initial therapy for idiopathic sudden sensorineural hearing loss: a meta-analysis. Acta Otolaryngol 2017;137:599–605.

[27] El Sabbagh NGSM, Bezjianian A, Daniel SJ. Intratympanic dexamethasone in sudden sensorineural hearing loss: a systematic review and meta-analysis. Laryngoscope 2017;127:1897–908.

[28] Crane RA, Camilon M, Nguyen S, et al. Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials. Laryngoscope 2015;125:209–17.

[29] Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol 2008;29:453–60.

[30] Chau JK, Cho JJ, Fritz DK. Evidence-based practice: management of adult sensorineural hearing loss. Otolaryngol Clin North Am 2012;45:941–58.

[31] Whittemore R, Knall K. The integrative review: updated methodology. J Adv Nurs 2005;52:546–53.

[32] Hong SM, Park CH, Lee JH. Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngol Head Neck Surg 2009;141:579–83.

[33] Higgs JP. Glic. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 The Cochrane Collaboration 2011. Updated March 2011.

[34] Guyatt GH, Kunz R, Woodcock J, et al. GRADE guidelines. 7 rating the quality of evidence-inconsistency. J Clin Epidemiol 2011;64:1294–302.

[35] Kosyakov S, Atanesyan A, Gunenkov A, et al. Intratympanic steroids for sudden sensorineural hearing loss. J Int Adv Otol 2011;7:323–32.

[36] Lim HJ, Kim YT, Choi SJ, et al. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngol Head Neck Surg 2013;148:121–7.

[37] Dispensa F, Amadio E, De Stefano A, et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. Eur Arch Otorhinolaryngol 2011;268:1273–8.

[38] Rauch SD, Halpin CF, Antonelli PJ, et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA 2011;305:2071–9.

[39] Ahn JH, You MH, Yoon TH, et al. Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness? Laryngoscope 2008;118:279–82.

[40] Arslan N, Ogas H, Demirci M, et al. Combined intratympanic and systemic use of steroids for idiopathic sudden sensorineural hearing loss. Otol Neurotol 2011;32:393–7.

[41] Park MK, Lee CK, Park KH, et al. Simultaneous versus subsequent intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2011;145:1016–21.

[42] Stokroos RJ, Albers FWJ, Schirm J. The etiology of idiopathic sudden sensorineural hearing loss: experimental herpes simplex virus infections of the inner ear. Am J Otol 1998;19:447–52.

[43] Nigura M, Iwasaki S, Wu R, et al. Effects of corticosteroid, contrast medium and ATP on focal microcirculatory disorders of the cochlea. Eur J Pharmacol 1999;366:47–53.

[44] Taubisch K, Okawa K, Uematoorni I, et al. Glucocorticoids and dehydroepiandrosterone sulfate ameliorate ischemia-injured island of the cochlea. Hear Res 2003;180:51–6.

[45] Lin DW, Trune DR. Breakdown of stria vascularis blood-labyrinth barrier in C3H/Pr autoimmune disease mice. Otolaryngol Head Neck Surg 1997;117:530–4.

[46] Plontke SKR, Salt AN. Quantitative interpretation of corticosteroid pharmacokinetics in inner fluids using computer simulations. Hear Res 2003;182:34–42.

[47] Plontke SK, Mikulec AA, Salt AN. Rapid clearance of methylprednisolone after intratympanic application in humans. Comment on: Bird PA, Begg EJ, Zhang M, et al. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007;28:1124–30. Otol Neurotol 2008;29:732–3.

[48] Schmuziger N, Probst R, Smrzyński J. Test-retest reliability of pure-tone thresholds from 0.5 to 1.6 kHz using Sennheiser HDA 200 and Etymotic Research ER-2 earphones. Ear Hear 2004;25:127–32.

[49] Kopele RD, Hoffer ME, Wester D, et al. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol 2001;22:475–9.